Page 176 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 176
Chapter 6b
Fig A1. Progression-free survival (PFS) by treatment arm for age-adjusted International Prognostic Index score.
(A) low, (B), low-intermediate, (C) high-intermediate, and (D) high. P, progression, relapse, or death; R-CHOP, rituximab on day 1 of each cycle plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm A); RR-CHOP, rituximab on days 1 and 8 of first 4 cycles and day 1 of remaining cycles plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm B).
174
